The Leeds CaReMe Innovative Clinic
@CaReMeLeeds
Followers
184
Following
3K
Media
6
Statuses
1K
The innovative CardioRenalMetabolic clinic in Leeds. Part of the innovative cardiology services.
Leeds, England
Joined June 2022
🎯Closing in on cholesterol: delivering cardiovascular prevention across the NHS A blog of national leaders of CVD Prevention at @NHSEngland. Tackling cholesterol beyond the National Cholesterol Awareness Month. #NCM25 @heartukcharity
@society_eas
https://t.co/XUFmPEfAnI
0
3
5
We developed two videos to address common questions about using injectables with cardiovascular benefits. 🎥 1️⃣ Targets Common Questions by healthcare professionals 🎥 2️⃣ Targets Common Questions by patients.
New @escardio @ACNAPPresident Educational Resources on a Selection of Injectable Therapies with Cardiovascular Benefits. Excellent tips for HCPs & patients addressing main practical points & questions. Well done InnoMeds team @LeedsHospitals. Link: https://t.co/GWLkGfqsGI
0
2
4
New @escardio @ACNAPPresident Educational Resources on a Selection of Injectable Therapies with Cardiovascular Benefits. Excellent tips for HCPs & patients addressing main practical points & questions. Well done InnoMeds team @LeedsHospitals. Link: https://t.co/GWLkGfqsGI
4
11
19
Patient friendly animations about cholesterol. https://t.co/e0ndTt5Mbq
youtube.com
This series of short animated videos describe the importance of understanding cholesterol, the problems caused by blood fats being out of balance, and how to...
0
2
2
Our Heart Failure Academy will be running a fabulous HF update in York on the 16th October 2025. It is targeted at none Heart Failure specialists. Visit @_HF_Academy_ Full details & registration are here: https://t.co/V1K0rFb2uS
1
9
13
CVD can lead to mental health conditions, such as depression, anxiety or stress, and vice versa. Here is the patient friendly version of the @ESC_Journals Clinical Consensus Statement on Mental Health & CVD. https://t.co/NCNdbhKL3h
0
3
8
People with high blood pressure. Walking more & faster - up to 10,000 steps ⬇️ risk of CVD. Every extra 1,000 steps / day (up to 10,000) ⬇️ risk of: ⭕️ overall CV risk by 17% ⭕️ HF by 22% ⭕️ MI by 9% ⭕️ Stroke by 24% https://t.co/yRmndD4c4O
0
11
11
Join our @_HF_Academy_ webinar on the 10th Sept at 19:30: "Challenges in heart failure medicines optimisation Q&A webinar" A panel discussion to identify ways to overcome challenges in heart failure medicines optimisation. Register here 👇 https://t.co/bgPNDNNQsv
0
10
18
New updated @NICEComms Heart Failure Guidelines. 🔘 HFrEF - offer RAASi + BB + MRA + SGLT2i 🔘 HFmrEF - SGLT2i + consider: RAASi + BB + MRA 🔘 HFpEF - SGLT2i + consider: MRA https://t.co/U802XHqy8N
1
18
41
Please join us today (Monday 1st Sept) at Science Box 5. Our @NHSEngland team will be presenting at 11am .. "Inequalities in cholesterol management for patients with CVD: findings from CVDPREVENT" #ESCCongress
#Lipids
4
14
23
Please visit our Heart Failure Academy and watch our 8 educational videos that Navigate the Heart Failure Journey. https://t.co/s6E4uq2gtJ
0
13
16
The #POTCAST Trial : Potassium optimization improved arrhythmia outcomes, safe in high-risk pts ⚡ POTCAST Trial (Denmark, n=1,200, high VT/ICD risk, K⁺ ≤4.3 mmol/L) 📌Intervention: K⁺ uptitration (target 4.5–5.0) vs std care 📌↑ K⁺ to 4.36 vs 4.05 mmol/L 📌Primary
3
13
51
2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease. Effect of different antipsychotics on cardiovascular risk factors. #ESCCongress #HeartDrugs #Pharmacotherapy
0
5
12
The AIM-HY INFORM at @escardio ESC Congress 2025 ▫️ethnicity matters for HTN treatment. ▫️Black patients: amlodipine & chlortalidone ⬇️ BP ~11 mmHg > ACEi ▫️ South Asian: amlodipine & chlortalidone ⬇️ BP ~4 mmHg > ACEi #ESCCongress #Pharmacotherapy
0
10
26
Beta Blockers post MI with EF >40% ▫️Not associated with a reduction in composite death, MI, HF ▫️mildly reduced EF might benefit ▫️need to explore potential harm in women with EF 50% or above #ESCCongress
#Pharmacotherapy
1
17
37
β-blockers post MI with EF of ≥ 40%. Meta-analysis. BB in mildly reduced EF ➡️ significant ⬇️ in composite outcome of all-cause death, new MI, or HF. Further research should focus on patients with preserved LVEF (>50%). #ESCCongress
#Pharmacotherapy
https://t.co/qLchecrdeE
0
24
48
Baxdrostat (BaxHTN) Good reduction of BP in those with uncontrolled and resistant hypertension. (-15mmHg with 2mg). Durability of BP lowering post stopping was notable and worth exploring. #ESCCongress
#Pharmacotherapy
2
26
71
Zilebesiran (KARDIA3) Reduces BP in patients with uncontrolled hypertension (on 2-4 meds) at high CV risk eGFR ≥45. More BP reduction in those on a diuretic. Not statistically significant. #ESCCongress
#Pharmacotherapy
1
12
29